Observed Signal · Oct 2, 2026 · Market Signal · Source: Johnson & Johnson · Impact: 4/5
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
MARKET SIGNALS
Track Johnson & Johnson Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Isomorphic Labs seeks $5B round at $50B valuation
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
Johnson & Johnson Furnishes Q3 2026 Earnings Announcement via Current Report
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
DeepIntent launches agentic ad platform Cora for pharma marketing
DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.
WATCHLIST & BRIEFINGS
Receive future signals for Johnson & Johnson & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor Johnson & Johnson
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
